Development And Evaluation Of Felbinac-Loaded Nanoparticle-Based Transdermal Patches For Sustained AntiInflammatory Therapy

Abstract

The present study aimed to develop and evaluate felbinac-loaded transdermal patches using a nanoparticle-based drug delivery system for sustained anti-inflammatory action. Various formulations (F1–F6) were prepared using different polymers and plasticizers, with F4 identified as the optimized formulation. The patches were evaluated for physicochemical properties including thickness, folding endurance, moisture content, tensile strength, and drug content. Formulation F4 exhibited the highest tensile strength (0.889 kg/cm²), excellent folding endurance (289±4), and drug content (98.85±0.45%). In vitro drug release studies revealed a sustained release of 89.98% over 12 hours, following Higuchi kinetics (R² = 0.991) with non-Fickian diffusion behavior. Stability studies confirmed F4’s physical and chemical stability under accelerated conditions. Skin irritation testing showed no signs of dermal toxicity. Pharmacodynamic evaluation using the carrageenan-induced paw edema model demonstrated significant anti-inflammatory activity of F4 compared to control. Overall, the results suggest that felbinac-loaded nanoparticle-based transdermal patches offer a promising and effective approach for sustained drug delivery and improved patient compliance.